Crinetics Pharmaceuticals (NASDAQ:CRNX) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) from a sell rating to a hold rating in a research report report published on Saturday.

A number of other equities analysts have also recently issued reports on CRNX. Morgan Stanley upped their price objective on Crinetics Pharmaceuticals from $77.00 to $80.00 and gave the stock an “overweight” rating in a report on Tuesday, January 6th. Lifesci Capital upgraded shares of Crinetics Pharmaceuticals to a “strong-buy” rating in a research report on Friday, February 13th. The Goldman Sachs Group upgraded shares of Crinetics Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $67.00 price objective for the company in a report on Monday, January 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Crinetics Pharmaceuticals in a research note on Wednesday, January 21st. Finally, Citizens Jmp decreased their target price on shares of Crinetics Pharmaceuticals from $108.00 to $105.00 and set a “market outperform” rating on the stock in a research report on Thursday, January 8th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Crinetics Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $75.78.

Crinetics Pharmaceuticals Price Performance

CRNX stock opened at $41.10 on Friday. The firm has a 50 day simple moving average of $48.83 and a two-hundred day simple moving average of $43.21. The stock has a market cap of $4.20 billion, a PE ratio of -8.32 and a beta of 0.19. Crinetics Pharmaceuticals has a one year low of $24.10 and a one year high of $57.99.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($1.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.08. The company had revenue of $3.89 million during the quarter, compared to the consensus estimate of $4.32 million. Crinetics Pharmaceuticals had a negative net margin of 6,046.22% and a negative return on equity of 39.91%. The firm’s revenue was up NaN% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.88) EPS. On average, research analysts expect that Crinetics Pharmaceuticals will post -3.73 EPS for the current fiscal year.

Insider Buying and Selling

In other Crinetics Pharmaceuticals news, insider Isabel Kalofonos sold 2,500 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $55.00, for a total value of $137,500.00. Following the sale, the insider owned 834 shares of the company’s stock, valued at $45,870. This trade represents a 74.99% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.60% of the stock is owned by corporate insiders.

Institutional Trading of Crinetics Pharmaceuticals

Large investors have recently modified their holdings of the business. Invesco Ltd. increased its holdings in Crinetics Pharmaceuticals by 76.8% during the 4th quarter. Invesco Ltd. now owns 158,089 shares of the company’s stock valued at $7,359,000 after purchasing an additional 68,696 shares during the period. ADAR1 Capital Management LLC increased its stake in shares of Crinetics Pharmaceuticals by 24.6% during the fourth quarter. ADAR1 Capital Management LLC now owns 309,368 shares of the company’s stock valued at $14,401,000 after buying an additional 61,000 shares during the period. Virtus Investment Advisers LLC increased its stake in shares of Crinetics Pharmaceuticals by 282.7% during the fourth quarter. Virtus Investment Advisers LLC now owns 13,535 shares of the company’s stock valued at $630,000 after buying an additional 9,998 shares during the period. Progeny 3 Inc. bought a new position in shares of Crinetics Pharmaceuticals during the fourth quarter valued at approximately $1,117,000. Finally, RTW Investments LP boosted its holdings in Crinetics Pharmaceuticals by 54.9% in the fourth quarter. RTW Investments LP now owns 1,351,326 shares of the company’s stock valued at $62,904,000 after acquiring an additional 478,939 shares in the last quarter. 98.51% of the stock is owned by institutional investors.

Trending Headlines about Crinetics Pharmaceuticals

Here are the key news stories impacting Crinetics Pharmaceuticals this week:

• Positive Sentiment: Q4 EPS beat consensus: Crinetics reported a narrower-than-expected loss (GAAP EPS of -$1.29 vs. the -$1.37 consensus), which can be viewed as a modest positive on execution vs. expectations. MarketBeat Earnings Summary
• Positive Sentiment: Management emphasized product launch momentum and provided a business update on the earnings call, signaling commercial progress that could support future revenue growth if sustained. Earnings Call Highlights
• Neutral Sentiment: Full earnings materials and transcripts published — investors can review the call transcript and slides for detail on guidance, launch metrics and timing. Seeking Alpha Transcript Slide Deck
• Neutral Sentiment: Reported short-interest data in system appears inconclusive/zeroed out for February (no actionable increase). This entry likely has no material impact until validated by official exchanges.
• Negative Sentiment: Revenue missed Street expectations (reported ~$3.9M vs. ~$4.3M consensus) and the company’s quarterly loss widened year-over-year — a revenue shortfall and rising losses can pressure sentiment, especially for a company transitioning to commercial sales. Zacks Earnings Note
• Negative Sentiment: Analysts and commentators flagged a new shelf/ESOP registration alongside discussion of product launch momentum — while the shelf can enable capital raises and fund commercialization, it also raises near-term dilution concerns that can hurt the share price. Yahoo Analysis

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company’s proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics’ research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company’s lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.